October 5th, 2026Decipher may help identify ADT benefit in intermediate-risk prostate cancerAn analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.Read more
September 28th, 2026A rising tide that lifts all boats: PSMA-PET and genomic testing for prostate cancerUsing PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.Read more
October 9th, 2026FDA grants 510(k) clearance to OpenFlo urinary catheterOpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.Read more
October 9th, 2026How can urologists separate personalized medicine from marketing?Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.Read more
October 9th, 2026FDA grants fast track designation to VIR-5500 for mCRPCVIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.Read more
October 8th, 2026Why ctDNA serves as a rule-out in NeoBLAST's response assessmentMarie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance. Read more
October 8th, 2026How should urologists coordinate IVF bladder symptom care?Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.Read more
October 7th, 2026US hospitals expand CAUTI prevention, but key practices remain variableA national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.Read more